

# Big Data for Public Health – Public Data for Big Health

Stefan Thurner



MEDICAL UNIVERSITY  
OF VIENNA



SANTA FE INSTITUTE



COMPLEXITY  
SCIENCE  
HUB  
VIENNA

[www.complex-systems.meduniwien.ac.at](http://www.complex-systems.meduniwien.ac.at)

[www.santafe.edu](http://www.santafe.edu)

with

Peter Klimek, Silke Aichberger, Anna Chmiel

supported by



EC FP7 projects LASAGNE and MULTIPLEX

date — patient ID — HCP ID — location — diagnosis — side  
diagnoses — prescription — price of generic drug/treatment  
— pharmacy ID — price of drug — date of purchase





100.000.000 lines per year

# Data set

→ medical claims data

for **every** paid **healthcare service** there is one data line

# Data set

- 8,000,000 patients
- 100,000,000 patient visits per year
- 2,000,000 hospitalisations per year
- 12,000 health care providers
- 6,102 diseases (ICD10 code)
- 1,171 drugs (ATC code)
- 255 hospitals
- 1,238 pharmacies

# Network medicine

# Co-morbidity networks


**starting point:** usually patients have more than one disease  
which diseases occur together? → **co-morbidity networks**

co-morbidity networks = health state of population (phenotype)

what can we learn from **co-morbidity networks**?


# What is a co-morbidity network?

co-occurrence of diseases in population




diseases ‘linked’ if many patients have both at same time

# Co-morbidity network of Austria




# The co-morbidity network: children





# The co-morbidity network: adults age 40-48




# Empirical finding

the way individual diseases occur = diffusion on these networks

A Chmiel, P Klimek, S Thurner, New Journal of Physics 16, 115013, (2014)


# Prediction of health trajectories

# Co-morbidity networks allow predictions



# Co-morbidity networks allow predictions: DM

if have diabetes what is odds ratio to have any other disease?



P Klimek, A Kautzky, A Chmiel, S Thurner, PLoS Comput Biol 11(4): e1004125 (2015)

# Co-morbidity network of diabetes explains ...


- analysis equivalent to 40,000 individual epidem. studies
- check which co-morbidity is causal
- confirm controversial relation of increased risk for Parkinson
- gender differences in progression of congestive heart failure
- females lower risk of hypertension during fertile age
- type 1 diabetes **leads** detection of depressions
- schizo-affective disorders **lead** type 2 diabetes, suggesting similar pathogenic or medication-related mechanisms

P Klimek, A Kautzky, A Chmiel, S Thurner, PLoS Comput Biol 11(4): e1004125(2015)

# Efficacy of prevention



# Co-morbidity networks and prevention



identify co-morbidities – check ‘causality’ – treat cause



# New classification of diseases


# What is Diabetes?

Observe:

diabetes co-occurs with other diseases in robust patterns

→ **allows us to classify diabetes differently**

# New “types” of diabetes – defined by co-morbidity



define new phenomenological types of DM through co-morbidity

# Which drug / therapy works?

- take a disease for which 2 therapies exist A and B
- compute all co-morbidities following therapy A
- compute all co-morbidities following therapy B
- compare: follow up costs, hospitalization time, co-morbidities

# How genetic is your disease?

# What explains a disease?

- genetic factors
- metabolic factors
- environmental / toxicogenetic factors
- epigenetic factors

# How genetic is diabetes?

Genes associated with diabetes type 2

• HHEX/IDE/KIF11 • TCF7L2 • KCNJ11 • MTNR1B •  
HNF1A • FTO • GCKR • PPARG • ADCY5 • CDKAL1 •  
SLC30A8 • CRY2 • FADS1


type 2 diabetes 25% hereditary

5-10% of variance explained by gene variants\*


→ **hard to tell!**

\* ME Travers MI McCarthy, Human Genetics 130 41-58 (2011)






Drug A



Drug A

# Compare co-morbidity and genotype networks



if co-morbidity network is “similar” to genetic network  $\rightarrow$  yes  
it is genetic

# Ranking of likelihood of genetic cause in multi-factoral diseases

- compute “similarity” between phenotypic and genetic network
- **hypothesis:** the more similar – the “more” genetic influence
- rank multi-factoral diseases wrt similarity in pheno-geno networks

only take cases that are unlikely to be of statistical origin  
 $p < 0.00001$

## Type 1 diabetes mellitus

Transient cerebral ischemic attacks and related syndromes	E10	0,50
Benign neoplasm of colon, rectum, anus and anal canal	G45	0,50
Eating disorders	D12	0,33
Polycythemia vera	F50	0,33
Other diseases of intestine	D45	0,25
Other cerebrovascular diseases	K63	0,25
Other and unsp diseases of blood and blood-forming organs	I67	0,21
Other congenital malformations of heart	D75	0,21
Malignant neoplasm of heart, mediastinum and pleura	Q24	0,20
Mesothelioma	C38	0,16
Specific personality disorders	C45	0,16
Overweight and obesity	F60	0,16
Other cardiac arrhythmias	E66	0,13
Cerebral infarction	I49	0,13

## Type 2 diabetes mellitus

Secondary parkinsonism	E11	0,11
Other and unspecified myopathies	G21	0,11
Congenital malformations of cardiac chambers and connections	G72	0,11
Other congenital malformations of eye	Q20	0,10
Congenital malformations of aortic and mitral valves	Q15	0,09
Parkinsons disease	Q23	0,09
	G20	0,08





Essential (primary) hypertension

Anoph

G71 with 0,07 May 24 2017 31

I10 0,07


Q11 0,06

# Classify multi-factoral diseases

- do the same with metabolic, environmental, pathway networks

→ **every disease gets assigned 3 numbers:**


- genetic rank
- toxicogenetic rank
- pathway importance



# Side effects – personalized


# Side effect networks

you have disease  $x \rightarrow$  get medication  $y \rightarrow y$  causes disease  $z$







# Side effects for diabetes treatments: Insulin



# Side effects for treatment: Insulin+Statines



# What are the side effects of Metformin?



# Disclaimer


**NO medical statement are made here!**

- This reflects the *status quo* in the population only
- No understanding why
- No mechanism clarified
- No medical understanding
- Need experts for this


# A telescope into the past

# Unexpected causes for diabetes?


take all  $\sim 300.000$  diabetes patients. Fraction of patients in population given birth date?  $\rightarrow$  **famines in Austria**



**Message:** mother suffers hunger in pregnancy  $\rightarrow$  baby develops diabetes in later life S Thurner et al. PNAS 110, 4703-4707, (2013)





# A window into the past II






# A window into the past II







# Vizualize healthcare system


# The healthcare system is ...

- network of patient flows
- network of information flows
- network of cash flows
- it is a co-evolving multi-layer network !

# Patient-flow network


- many patient flows are medically reasonable – many are not
- health care costs can be completely transparent – if wanted
- patient flows + comorbidity across age → future costs

# Patient-flow network as we like it





-  General practitioner
-  Medical specialist
-  Pharmacy
-  Hospital

# Patient-flow network







# Patient-flow network of Austria 2006



# Patient-flow network: patterns



Dorda W, et al. Analyse von Behandlungsnetzwerken (HVB, 2013)




# With this information one can monitor ...

- regional differences in quality of care / prescriptions / success rates / diagnoses / costs / transparency /
- 'cyclic flows': which ones are medically necessary?
- success of prevention schemes (medical & economic)
- nation-wide behaviour of patients: drug use, vaccination rates
- visiting frequency as function of accessibility of HCP
- optimal health care coverage densities

# Vision

- 1:1 agent based model of the Austrian health care system
- use data to fully calibrate the model
- estimate how individual patients take decisions
- estimate how HCP take decisions
- make policy experiments: insurers and politicians








Day:549

#Visits:2871




Start the visualization press the start/stop button on the right.

Stop the visualization press the turtle.

Switch between doctors activity and patients paths use the transparent button on the upper left.

DOCTOR POSITION IS FIXED AT RANDOM







# Summary

- begin to predict health trajectories from co-morbidity networks
- see which medication works
- make gender differences visible
- compute personalized side effects
- new classification of diseases in terms of co-morbidity
- compute medical and economical value of prevention schemes
- quantify resilience, robustness, sustainability of health care system

# Collaboration partners – experts

Alexandra Kautzky-Willer, MUW

Gottfried Endel, Hauptverband

Miriam Leitner, MUW

Irmgard Schiller-Frühwirth, Hauptverband

Herwig Ostermann, Gesundheit Österreich

Klaus Kratochwill, MUW

# Statistics

- Phenotype NW:  $\phi$  is correlation coefficient (binary), Kramers coefficient

- Relative Risk:

$$\frac{a/(a + c)}{b/(b + d)}$$

- Odds Ratio:

$$\frac{P(A)(1 - P(B))}{P(B)(1 - P(A))}$$

where  $P(A) = a/(a + c)$  and  $P(B) = b/(b + d)$